Shares of HCA Holdings Inc (NYSE:HCA) ended Thursday session in red amid volatile trading. The shares closed down -0.18 points or -0.23% at $75.26 with 2.45 million shares getting traded. Post opening the session at $75.39, the shares hit an intraday low of $74.67 and an intraday high of $76.04 and the price vacillated in this range throughout the day. The company has a market cap of $28.61 billion and the numbers of outstanding shares have been calculated to be 378.65 million shares.
HCA Holdings Inc (HCA) on September 7, 2016 announced the signing of an agreement to purchase Mobile Heartbeat, a leading developer of applications for smartphones to improve clinical workflow and team communications. Mobile Heartbeat technology solutions consolidate clinical communications, including alarms and notifications, patient information and lab data, secure texting, voice and photography.
HCA recently completed a successful pilot of Mobile Heartbeat’s CURE™ (Clinical Urgent Response) technology for its iMobile Project, an initiative to implement smartphone-based critical care team communications. HCA is launching Mobile Heartbeat’s CURE technology in 21 hospitals across the country with plans to implement the technology enterprise-wide.
“Mobile Heartbeat is an innovator that is keenly focused on meeting the mobile technology needs of clinicians,” said Dr. Jonathan Perlin, HCA’s chief medical officer and president of the Clinical Services Group. “This acquisition will enhance our ability to work closely with Mobile Heartbeat as we continue to create and refine technology solutions to improve clinical workflows and provide secure communications that foster better patient care.”
Shares of TherapeuticsMD Inc (NYSEMKT:TXMD) ended Thursday session in red amid volatile trading. The shares closed down -0.12 points or -1.77% at $6.65 with 2.70 million shares getting traded. Post opening the session at $6.61, the shares hit an intraday low of $6.59 and an intraday high of $6.78 and the price vacillated in this range throughout the day. The company has a market cap of $1.32 billion and the numbers of outstanding shares have been calculated to be 196.49 million shares.
TherapeuticsMD Inc (TXMD) on September 20, 2016 announced the acceptance of the NDA for Yuvvexy, the conditionally-approved trade name for TX-004HR, by the U.S. Food and Drug Administration (FDA). Yuvvexy is an investigational bio-identical 17β-estradiol vaginal softgel capsule for the treatment of moderate-to-severe vaginal pain during sexual intercourse (dyspareunia), a symptom of vulvar vaginal atrophy (VVA) in postmenopausal women.
The NDA acceptance by the FDA in its 74-day letter indicates that the application is sufficiently complete to permit a substantive review. The PDUFA target action date for the completion of the FDA’s review is May 7, 2017.
“The acceptance of the NDA for Yuvvexy is an important milestone for TherapeuticsMD as we pursue our goal to provide women with novel healthcare solutions that address their needs throughout life,” said TherapeuticsMD CEO Robert G. Finizio. “If approved, Yuvvexy has the potential to be a highly differentiated treatment option for the 32 million postmenopausal women in the United States who suffer from symptoms of VVA. Yuvvexy is the first product candidate from our pipeline of novel hormone therapies in development to address women’s unmet health needs.”